📣 VC round data is live. Check it out!
- Public Comps
- Korro Bio
Korro Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Korro Bio and similar public comparables like Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova and more.
Korro Bio Overview
About Korro Bio
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Founded
2014
HQ

Employees
104
Website
Financials (LTM)
EV
$97M
Valuation Multiples
Start free trialKorro Bio Financials
Korro Bio reported last 12-month revenue of $5M and negative EBITDA of ($103M).
In the same LTM period, Korro Bio generated $5M in gross profit, ($103M) in EBITDA losses, and had net loss of ($102M).
Revenue (LTM)
Korro Bio P&L
In the most recent fiscal year, Korro Bio reported revenue of $6M and EBITDA of ($83M).
Korro Bio is unprofitable as of last fiscal year, with EBITDA margin of (1298%) and net margin of (1832%).
Financial data powered by Morningstar, Inc.
Korro Bio Stock Performance
Korro Bio has current market cap of $169M, and enterprise value of $97M.
Market Cap Evolution
Korro Bio's stock price is $11.68.
Korro Bio share price decreased by 13.2% in the last 30 days, and increased by 2.3% in the last year.
Korro Bio has an EPS (earnings per share) of $-8.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $97M | $169M | 4.3% | -13.2% | -3.7% | 2.3% | $-8.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKorro Bio Valuation Multiples
Korro Bio trades at 21.4x EV/Revenue multiple, and (0.9x) EV/EBITDA.
EV / Revenue (LTM)
Korro Bio Financial Valuation Multiples
As of May 23, 2026, Korro Bio has market cap of $169M and EV of $97M.
Korro Bio has a P/E ratio of (1.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Korro Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Korro Bio Margins & Growth Rates
Korro Bio decreased revenue by 74% and EBITDA by 3% in the last fiscal year.
In the most recent fiscal year, Korro Bio reported EBITDA margin of (1298%) and net margin of (1832%).
Korro Bio Margins
Korro Bio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Korro Bio Operational KPIs
Korro Bio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Korro Bio's Rule of 40 is (4888%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Korro Bio's Rule of X is (4999%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Korro Bio Competitors
Korro Bio competitors include Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova, Vitrafy, Curiosis, Bioventix, Atlantic International, Genomictree and ArcticZymes.
Most Korro Bio public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech, DeepTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 11.5x | 19.1x | (8.7x) | (7.6x) | |||
| 4.1x | 3.2x | 48.1x | 15.6x | |||
| 42.3x | 51.9x | (6.5x) | (6.4x) | |||
| 5.4x | 5.2x | (32.5x) | (30.2x) | |||
| 2253.8x | 88.5x | (11.8x) | (8.7x) | |||
| 41.9x | 28.5x | (46.3x) | (79.1x) | |||
| 6.2x | 6.4x | 8.0x | 8.5x | |||
| 0.5x | 0.5x | (4.6x) | — | |||
This data is available for Pro users. Sign up to see all Korro Bio competitors and their valuation data. Start Free Trial | ||||||
Korro Bio Funding History
Before going public, Korro Bio raised $208M in total equity funding, across 2 rounds.
Last private valuation of Korro Bio was $325M, after raising $116M in January 2022 from Eventide.
Korro Bio Funding Rounds
Korro Bio M&A Activity
Korro Bio has acquired 1 company to date.
Last acquisition by Korro Bio was on July 14th 2023. Korro Bio acquired Frequency Therapeutics for $117M (EV/Revenue multiple of ).
Latest Acquisitions by Korro Bio
| Description | Frequency Therapeutics is a biotechnology firm developing small-molecule drugs that regenerate auditory sensory cells to treat hearing loss. Its lead candidate FX-322 targets noise-induced and age-related conditions through transient progenitor cell activation. Woburn-headquartered and founded in 2014, the company advanced FX-322 into Phase 2b clinical trials by 2021. Frequency Therapeutics focuses on inner ear therapeutics without cell or gene therapy complexities, with operations in the United States. |
| HQ Country | |
| HQ City | Lexington, KY |
| Deal Date | 14 Jul 2023 |
| Valuation | $117M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Korro Bio acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Korro Bio
| When was Korro Bio founded? | Korro Bio was founded in 2014. |
| Where is Korro Bio headquartered? | Korro Bio is headquartered in United States. |
| How many employees does Korro Bio have? | As of today, Korro Bio has over 104 employees. |
| Who is the CEO of Korro Bio? | Korro Bio's CEO is Ram Aiyar. |
| Is Korro Bio publicly listed? | Yes, Korro Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Korro Bio? | Korro Bio trades under KRRO ticker. |
| When did Korro Bio go public? | Korro Bio went public in 2023. |
| Who are competitors of Korro Bio? | Korro Bio main competitors include Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova, Vitrafy, Curiosis, Bioventix, Atlantic International, Genomictree, ArcticZymes. |
| What is the current market cap of Korro Bio? | Korro Bio's current market cap is $169M. |
| What is the current revenue of Korro Bio? | Korro Bio's last 12 months revenue is $5M. |
| What is the current revenue growth of Korro Bio? | Korro Bio revenue growth (NTM/LTM) is (69%). |
| What is the current EV/Revenue multiple of Korro Bio? | Current revenue multiple of Korro Bio is 21.4x. |
| Is Korro Bio profitable? | No, Korro Bio is not profitable. |
| What is the current EBITDA of Korro Bio? | Korro Bio has negative EBITDA and is not profitable. |
| What is Korro Bio's EBITDA margin? | Korro Bio's last 12 months EBITDA margin is (2267%). |
| What is the current EV/EBITDA multiple of Korro Bio? | Current EBITDA multiple of Korro Bio is (0.9x). |
| How many companies Korro Bio has acquired to date? | As of May 2026, Korro Bio has acquired 1 company. |
| What was the largest acquisition by Korro Bio? | $117M acquisition of Frequency Therapeutics on 14th July 2023 was the largest M&A Korro Bio has done to date. |
| What companies Korro Bio acquired? | Korro Bio acquired Frequency Therapeutics. |
| In how many companies Korro Bio has invested to date? | Korro Bio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Korro Bio
Lists including Korro Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
